GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aptorum Group Limited
Aptorum is a diversified pharmaceutical company with a broad development pipeline. Its stock price reflects progress across all its programs. Its stock price is volatile and driven by lab and regulatory updates.
Share prices of companies in the market segment - Pharma other
Aptorum Group is a biopharmaceutical company with a broad development portfolio, ranging from infectious disease treatments to oncology. We classified it in the "Other Pharma" category due to its diversification. The chart below reflects general trends and risks in the early-stage biotech sector.
Broad Market Index - GURU.Markets
Aptorum is a diversified pharmaceutical company developing drugs for a wide range of diseases. As a unique player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Aptorum's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
APM - Daily change in the company's share price Aptorum Group Limited
Aptorum Group Limited's daily share price fluctuations reflect the high volatility inherent in biotech companies with a wide range of developments. This indicator measures the company's sensitivity to news about various projects, from infectious diseases to oncology.
Daily change in the price of a set of shares in a market segment - Pharma other
Aptorum Group Limited is a diversified pharmaceutical company. This chart demonstrates the sector's high volatility. Comparison with APM's performance, with its broad development portfolio, helps assess how diversification impacts its stability.
Daily change in the price of a broad market stock, index - GURU.Markets
Aptorum Group is a pharmaceutical company with a diversified development portfolio. Its shares react to news across multiple clinical programs. This complex, multi-factor dynamic contributes uniquely to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aptorum Group Limited
Aptorum Group Limited's annual performance tells the story of its diversified portfolio of pharmaceutical developments. Its 12-month market cap depends on progress across its numerous programs, from infectious diseases to oncology. Its valuation is a bet on at least one of its risky projects reaching the finish line.
Annual dynamics of market capitalization of the market segment - Pharma other
As an early-stage biotech company, Aptorum is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its diversified portfolio. Its stock price will reflect investors' speculative faith in its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aptorum Group, with its diversified development portfolio, is essentially a "biotech startup fund" in a single stock. Its performance relative to the market is the average of successes and failures across multiple verticals. This reduces the risk of a single drug failing while also mitigating potential explosive growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aptorum Group Limited
Aptorum is a diversified biopharmaceutical company. Its monthly performance reflects news across its many preclinical and clinical programs. Progress in any of them, from infectious diseases to oncology, can impact its valuation.
Monthly dynamics of market capitalization of the market segment - Pharma other
Aptorum Group is a pharmaceutical company developing a portfolio of drugs for the treatment of various diseases, including infectious diseases and oncology, often targeting unmet medical needs. The chart below illustrates the overall dynamics of the biotech sector, where a diversified approach can mitigate risks.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aptorum Group is a diversified pharmaceutical company with numerous drugs in early development. Its shares are volatile and move based on news about any of its projects. Diversification may mitigate some risks, but its performance remains disconnected from the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aptorum Group Limited
Aptorum Group is a biopharmaceutical company with a broad, albeit early-stage, pipeline. Its weekly share price performance is volatile, reflecting speculative investor interest in its diverse research projects.
Weekly dynamics of market capitalization of the market segment - Pharma other
Aptorum Group is a pharmaceutical company with a wide range of developments. This chart helps investors understand how its diversified portfolio impacts its weekly stock performance relative to the sector. Does this smooth out volatility or, conversely, create unpredictable movements?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aptorum Group Limited is a pharmaceutical company whose shares follow the rhythm of news about clinical trials and partnerships. The chart clearly shows how its weekly performance is detached from the broader market, moving along its own unique trajectory.
Market capitalization of the company, segment and market as a whole
APM - Market capitalization of the company Aptorum Group Limited
Aptorum Group's market capitalization reflects a diversified bet on pharmaceutical developments. The chart of this holding company, with a portfolio of projects ranging from infectious diseases to oncology, shows how investors view its risky model, which relies on multiple early-stage developments.
APM - Share of the company's market capitalization Aptorum Group Limited within the market segment - Pharma other
Aptorum Group is a diversified pharmaceutical company developing drugs for the treatment of various diseases, including infectious diseases and oncology. Its market capitalization within its segment reflects its broad, yet risky, early-stage pipeline. The company's weight is a composite assessment of the likelihood of success of its numerous research programs.
Market capitalization of the market segment - Pharma other
Aptorum Group is a biopharmaceutical company with a broad development portfolio. How big is this industry? The chart below shows the overall market capitalization of this sector. Its dynamics reflect how investors value platform companies that focus on several different technologies and therapeutic areas.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Aptorum Group chart shows how the market values a diversified biotech incubator. The market capitalization of a company developing drugs in various fields, from infectious diseases to oncology, is a measure of its ability to select and develop promising projects. This diagram illustrates the venture biotech model.
Book value capitalization of the company, segment and market as a whole
APM - Book value capitalization of the company Aptorum Group Limited
For Aptorum Group, a biopharmaceutical company, book value is its tangible assets, consisting of R&D assets, rights to drug candidates, and financial reserves for preclinical and clinical trials. The chart below shows how this scientific and financial capital was formed.
APM - Share of the company's book capitalization Aptorum Group Limited within the market segment - Pharma other
Aptorum Group Limited is a diversified pharmaceutical company. Its tangible assets include research laboratories and partner facilities where work is underway on a wide range of projects, from infectious diseases to oncology. The chart shows how its R&D infrastructure compares to other players in the sector.
Market segment balance sheet capitalization - Pharma other
Aptorum Group is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Aptorum focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Aptorum's assets represent more than just one drug; they constitute an incubator that initiates and develops multiple early-stage projects in various therapeutic areas, from infectious diseases to oncology. The book value reflects the total capital invested in this diversified portfolio.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aptorum Group Limited
Aptorum Group is a diversified pharmaceutical company with a broad but early pipeline. Its market capitalization is the combined value of its many projects. The chart shows how the market values this "biotech incubator" model, which diversifies risks but may lack focus.
Market to book capitalization ratio in a market segment - Pharma other
Aptorum Group is a biopharmaceutical company with a diversified development portfolio. The chart shows how the market values its projects at various stages, from infectious diseases to oncology, comparing expectations with its current assets.
Market to book capitalization ratio for the market as a whole
Aptorum Group is a pharmaceutical company with a diversified development pipeline. Its valuation is the sum of expectations for each potential drug. This chart shows how investors evaluate the platform approach in biotech, where value is created through a broad range of research rather than a single product.
Debts of the company, segment and market as a whole
APM - Company debts Aptorum Group Limited
Aptorum Group is a pharmaceutical company with a broad pipeline of early-stage candidates. Supporting multiple research projects simultaneously requires a diversified approach to funding. This chart shows how the company raises capital to advance its numerous research projects, from infectious diseases to oncology.
Market segment debts - Pharma other
Aptorum Group is a biopharmaceutical company with a diversified portfolio of early-stage projects. Funding such a broad range of research requires significant resources. This chart shows its financial position and how it allocates capital across its numerous R&D programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aptorum Group Limited
Aptorum Group is a biopharmaceutical company with a broad development pipeline. This chart shows its financial structure. For a company with multiple early-stage projects, it's crucial to have sufficient capital. The debt burden in such a situation could be unsustainable if none of the projects quickly achieve commercial success.
Market segment debt to market segment book capitalization - Pharma other
Aptorum Group is a biopharmaceutical company with a broad portfolio of early-stage projects, ranging from infectious diseases to oncology. This diversified approach requires significant capital. The chart shows the overall debt burden in the sector, which helps assess how the company finances its numerous but risky R&D programs.
Debt to book value of all companies in the market
Aptorum Group Limited is a biopharmaceutical company with a broad portfolio of early-stage projects. Diversification increases its chances, but also requires more capital. This chart shows that to finance such a vast and risky R&D pipeline, the company can rely solely on equity rather than debt.
P/E of the company, segment and market as a whole
P/E - Aptorum Group Limited
For Aptorum Group, a pharmaceutical company with a broad and diverse development pipeline, the P/E ratio is not indicative. The company lacks stable profitability. Its valuation is a cumulative, speculative bet that at least one of its numerous projects in various medical fields will be successful.
P/E of the market segment - Pharma other
Aptorum Group is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic and diagnostic technologies for the treatment of diseases with unmet medical needs. This chart shows the average valuation for the sector, providing investors with context for evaluating Aptorum's diversified scientific portfolio.
P/E of the market as a whole
Aptorum Group is a biopharmaceutical company with a diversified portfolio of early-stage projects. Its valuation reflects investors' speculative expectations that at least one of its numerous projects will be successful. It is not linked to the general economic trends shown in this chart, but rather depends on lab data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aptorum Group Limited
Aptorum Group is a clinical-stage biopharmaceutical company developing drugs for a wide range of diseases, including infectious diseases and oncology. This chart reflects investors' speculative expectations for its diversified pipeline. The valuation is based on the likelihood of success of at least one of its projects.
%20P%2FE%20Aptorum%20Group%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aptorum-Group-Limited&v=1772513548556 "Chart of the company's future (projected) P/E Aptorum Group Limited")
Future (projected) P/E of the market segment - Pharma other
Aptorum Group is a pharmaceutical company with a diversified development portfolio, ranging from infectious diseases to oncology. Its valuation relative to other biotech companies reflects investors' perceptions of its "project incubator" strategy. This reflects how the market assesses its ability to bring at least one of its numerous projects to commercialization.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772513548602 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Aptorum Group is a pharmaceutical company with a broad but early pipeline of developments in various therapeutic areas. The company's strategy is to diversify risk. This chart shows the overall risk appetite of investors. For biotechs with a diversified but shallow portfolio, market optimism is important for funding multiple parallel projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513548616 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aptorum Group Limited
Aptorum Group is a biopharmaceutical company focused on developing treatments for infectious diseases and oncology. The financial indicators presented here reflect expenditures on a wide range of research programs. Success depends on the advancement of at least one of its projects through clinical trials.
Profit of companies in the market segment - Pharma other
Aptorum Group is a pharmaceutical company working on a wide range of drugs, from infectious diseases to oncology. This chart shows the overall profitability of the pharmaceutical industry. It helps assess how successful a diversified development portfolio strategy can be for a small company in a highly competitive environment.
Overall market profit
Aptorum Group is a pharmaceutical company working on a wide range of drugs, from infectious diseases to oncology. For the company, the key success factors in the research and development phase are scientific data and access to funding, not the overall economic situation, as reflected in this graph.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aptorum Group Limited
Aptorum Group is a pharmaceutical company with a diversified portfolio of developments targeting various diseases. Its future profit forecast is a cumulative assessment of the chances of success of its numerous projects. This chart shows whether analysts believe at least one of its developments will reach the commercial stage.
%20profit%20of%20the%20company%20Aptorum%20Group%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aptorum-Group-Limited&v=1772513548672 "Graph of future (projected) profit of the company Aptorum Group Limited")
Future (predicted) profit of companies in the market segment - Pharma other
Aptorum Group is a pharmaceutical company that discovers and develops new drugs for a wide range of diseases, often focusing on repurposing existing molecules. This chart shows forecasts for the pharmaceutical sector. It helps assess how the risky but potentially highly profitable R&D model compares to overall industry trends.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772513548692 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
The forecast in this chart determines the availability of financing for early-stage pharmaceutical companies. Aptorum Group, with its diversified development portfolio, requires a constant influx of capital. Economic growth facilitates raising capital, while recession and risk aversion can create difficulties.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513548728 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aptorum Group Limited
Aptorum Group is a biopharmaceutical company with a broad development pipeline. This metric reflects investors' combined assessment of the potential revenue from all of its projects, from infectious diseases to oncology.
P/S market segment - Pharma other
Aptorum Group is a pharmaceutical company with a diversified portfolio spanning drug development from infectious diseases to oncology. This chart shows the average valuation in the pharmaceutical sector. It helps assess how investors perceive Aptorum's broad, yet risky, strategy of developing multiple drugs.
P/S of the market as a whole
Aptorum Group Limited is a pharmaceutical company focused on the discovery and development of new drugs for the treatment of diseases with unmet medical needs. The company has a broad but early pipeline of projects. Its valuation reflects the optionality of these projects. This chart helps assess the risks of investing in companies at the R&D stage.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aptorum Group Limited
Aptorum Group is a biopharmaceutical company with a broad pipeline, ranging from infectious diseases to oncology. Its valuation is a combined bet on the success of several projects. The chart reflects investor expectations regarding the likelihood of at least one of its candidates being successful and generating significant revenue.
%20P%2FS%20Aptorum%20Group%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aptorum-Group-Limited&v=1772513548830 "The graph of the company's future (projected) P/S Aptorum Group Limited")
Future (projected) P/S of the market segment - Pharma other
Aptorum Group is a pharmaceutical company with a broad pipeline of developments targeting various diseases, including infectious diseases and oncology. The company often focuses on orphan (rare) diseases. This chart shows how investors value its diversified, yet early-stage, research pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772513548850 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
This reflects the overall sentiment of investors in the pharmaceutical industry. For Aptorum Group, a biotech company with a broad development pipeline, this is an indicator of capital availability. Market optimism allows the company to fund research in various fields, from infectious diseases to oncology, diversifying its risks.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513548874 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aptorum Group Limited
Aptorum Group is a diversified pharmaceutical company developing drugs to treat a wide range of diseases, including infectious diseases and oncology. This chart reflects revenue from licensing agreements and partnerships. Future revenue is dependent on the success of numerous clinical trial programs.
Sales of companies in the market segment - Pharma other
Aptorum Group is a diversified pharmaceutical company developing drugs in various therapeutic areas, including infectious diseases and oncology. This chart illustrates the overall dynamics of the pharmaceutical industry. Aptorum's broad portfolio reflects the diversity of approaches to discovering new treatments.
Overall market sales
Aptorum Group Limited is a pharmaceutical company developing drugs for the treatment of a wide range of diseases. Its development depends on funding and successful clinical trials. The overall economic situation, shown in this chart, influences investor willingness to invest in diversified biotech portfolios.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aptorum Group Limited
Aptorum Group is a diversified pharmaceutical company developing drugs in various fields, including infectious and metabolic diseases, as well as developing a diagnostic platform. This chart reflects aggregate analyst expectations for the company's entire early-stage pipeline.
%20sales%20of%20the%20company%20Aptorum%20Group%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aptorum-Group-Limited&v=1772513549032 "Schedule of future (projected) sales of the company Aptorum Group Limited")
Future (projected) sales of companies in the market segment - Pharma other
Aptorum Group is a biopharmaceutical company with a diversified portfolio, including drugs for infectious diseases and cancer. This chart shows expectations for the entire pharmaceutical sector, providing a general context for evaluating the company's strategy and developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772513549058 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Aptorum Group Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic drugs for the treatment of diseases with unmet medical needs. Its diversified portfolio depends on the success of its research. This schedule, reflecting the state of the economy, affects the availability of capital for R&D.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513549097 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aptorum Group Limited
Aptorum Group is a pharmaceutical company with a broad pipeline of early-stage developments. This chart reflects its research-focused business model. Negative values represent the company's spending on multiple projects, of which at least one is hoped to be successful, recouping all investments and generating profit.
Market segment marginality - Pharma other
Aptorum Group is a pharmaceutical company developing drugs for the treatment of a wide range of diseases, including infectious diseases. For a company in the research stage, this chart is an important benchmark. It reflects the average profitability in the pharmaceutical sector, demonstrating the potential financial return from the successful commercialization of their developments.
Market marginality as a whole
Aptorum Group is a pharmaceutical company developing drugs for the treatment of a wide range of diseases, including infectious diseases. This overall market profitability chart is not a determining factor for the company. Its future success depends on a diversified development portfolio and the ability to bring at least one project to commercialization.
Employees in the company, segment and market as a whole
Number of employees in the company Aptorum Group Limited
Aptorum Group is a biopharmaceutical company working across a wide range of therapeutic areas, from infectious diseases to oncology. This graph shows a small team managing a diverse portfolio of projects, many of which are in early stages of development.
Share of the company's employees Aptorum Group Limited within the market segment - Pharma other
Aptorum Group is a biopharmaceutical company with a broad development portfolio, ranging from infectious diseases to oncology. This chart shows the proportion of scientists and researchers with diverse specializations the company attracts. It reflects its diversified approach and ability to concentrate talent on a wide range of medical problems.
Number of employees in the market segment - Pharma other
Aptorum Group is a biopharmaceutical company working on a wide range of diseases, from infectious diseases to oncology. A diversified R&D portfolio requires a flexible scientific team. This chart illustrates the diverse strategies in biotech: some companies focus on a single target, while others, like Aptorum, conduct research in multiple areas.
Number of employees in the market as a whole
Aptorum Group, a diversified pharmaceutical company, demonstrates the industry's diversity. From research to production, the sector requires a wide range of specialists. This chart reflects total employment, with pharmaceuticals being one of the pillars, providing stable and well-paying jobs for hundreds of thousands of people.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aptorum Group Limited (APM)
Aptorum Group is a diversified pharmaceutical company. This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its broad, yet early, pipeline of developments (from infections to cancer). The chart demonstrates the high future value the market is pricing into these diverse research projects.
%20of%20the%20company%20Aptorum%20Group%20Limited%20(APM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aptorum-Group-Limited-APM&v=1772513549344 "Chart of market capitalization per employee (in thousands of dollars) of the company Aptorum Group Limited (APM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Aptorum Group is a pharmaceutical company with a wide range of developments. For such companies, capitalization per employee can reflect a diversified risk portfolio. The chart helps assess how the market, on average, values the potential of their various research programs and compares this with more focused biotech companies.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772513549347 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Aptorum Group Limited is a biopharmaceutical company developing new treatments. This chart represents the overall market performance metric. It helps evaluate the company's diversified development pipeline.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513549375 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aptorum Group Limited (APM)
Aptorum Group is a clinical-stage biotech company with no commercial products. This chart shows the net loss per employee. It reflects how much the company invests in each scientist to conduct R&D and discover new drugs.
%20Chart%20Aptorum%20Group%20Limited%20(APM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aptorum-Group-Limited-APM&v=1772513549398 "Company Profit Per Employee (in thousands of dollars) Chart Aptorum Group Limited (APM)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Aptorum Group is a diversified pharmaceutical company developing and commercializing a wide range of therapeutics. Its business model encompasses both early research and product launches. This chart provides an average view of its performance, demonstrating how the efforts of all employees, from scientists to marketers, translate into bottom line profits.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772513549546 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Aptorum Group (APM) is a diversified clinical-stage biopharmaceutical company developing drugs for the treatment of infectious diseases, cancer, and other diseases (including orphan drugs). This is an R&D business. This chart shows the market average dollar return per employee. For APM (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513549602 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aptorum Group Limited (APM)
Aptorum Group is a diversified pharmaceutical company developing and commercializing a variety of drugs. This chart is a summary indicator of its portfolio success, reflecting how successfully the company advances its projects from the idea stage to the revenue-generating stage.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aptorum-Group-Limited-APM&v=1772513549649 "Sales chart per company employee Aptorum Group Limited (APM)")
Sales per employee in the market segment - Pharma other
Aptorum Group is a diversified clinical-stage pharmaceutical company with a broad development pipeline. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Aptorum's staff within the industry.
Sales per employee for the market as a whole
Aptorum Group is a diversified pharmaceutical company engaged in both drug development and diagnostics. The company has no stable commercial revenue. This metric currently doesn't reflect its value, as the entire team is focused on various R&D projects rather than sales.
Short shares by company, segment and market as a whole
Shares shorted by company Aptorum Group Limited (APM)
Aptorum Group is a pharmaceutical "microcap" with a very broad and early pipeline (from infections to cancer). This chart shows that investors perceive this as a lack of focus. Bears are betting that the company is simply wasting its meager resources, with no chance of bringing any of its numerous speculative projects to market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aptorum-Group-Limited-APM&v=1772513549727 "Short Shares Chart for the Company Aptorum Group Limited (APM)")
Shares shorted by market segment - Pharma other
Aptorum Group Limited is a biopharmaceutical company working on a wide range of candidates, from infectious diseases to oncology, often at very early stages. This indicator reflects the overall volume of short positions in the pharmaceutical sector. An increase in short positions here may indicate that investors are skeptical of companies with a very broad but shallow pipeline.
Shares shorted by the overall market
Aptorum Group is a biotech holding with a very broad and fuzzy pipeline (from infections to neuroscience). This chart illustrates the overall market pessimism. When investors are fearful, they hate a "hodgepodge." They see R&D spending across multiple areas and don't believe any of them will succeed.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aptorum Group Limited (APM)
This chart for Aptorum is a barometer of biotech speculation. It's a holding company with a very broad and early-stage portfolio—from infectious disease treatments to cancer. "Overheating" (above 70) occurs on announcements of trial launches or general hype. A lack of focus, a constant need for capital, and the risk of failure on all fronts keep the shares "oversold."
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aptorum-Group-Limited-APM&v=1772513549891 "RSI 14 indicator chart for the company's stock Aptorum Group Limited (APM)")
RSI 14 Market Segment - Pharma other
Aptorum (APM) is a diversified biotech stock based in Hong Kong. They have a "basket" of diverse projects, from infections to oncology. The "Pharma Other" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is APM's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Aptorum Group (APM) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast APM (Aptorum Group Limited)
Aptorum Group is an early-stage biotech company with a highly diversified portfolio focused on rare diseases, oncology, and infectious diseases. This chart shows the analysts' average 12-month forecast, reflecting their speculative assessment of the potential of this broad but shallow R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-APM-Aptorum-Group-Limited&v=1772513550062 "A chart showing analyst consensus forecasts for the expected stock price. APM (Aptorum Group Limited)")
The difference between the consensus estimate and the actual stock price APM (Aptorum Group Limited)
Aptorum Group is an early-stage biotech holding company investing in the development of drugs for the treatment of infectious and metabolic diseases. This chart measures the gap between the current share price and the consensus target price. It shows how confident experts are in their diversified, yet very early R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-APM-Aptorum-Group-Limited&v=1772513550093 "A chart showing the difference between the consensus forecast and the actual stock price. APM (Aptorum Group Limited)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Aptorum Group is a biotech R&D holding focused on infectious and neurological diseases. It's a risky bet on "junior" biotech. This chart reflects analysts' overall expectations for the entire pharmaceutical sector. It shows whether experts believe in the success of small R&D companies.
Analysts' consensus forecast for the overall market share price
Aptorum Group is a Hong Kong-based biotech holding company with a highly diversified development portfolio (from infectious diseases to cancer). This chart reflects the overall market "risk appetite." For Aptorum, a high-risk, broad-focus company, overall market optimism (risk appetite) is critical to raising the capital needed to fund all of its projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aptorum Group Limited
Aptorum Group is a diversified micro-biotech holding company. They don't have a single bet; they manage a portfolio of R&D projects (from cancer to infections) and (uniquely) are trying to launch a bio-marketplace (SME). This chart is a summary indicator of their portfolio strategy. It reflects their (very risky) R&D pipeline and their (speculative) bets on new business models.
AKIMA Market Segment Index - Pharma other
Aptorum Group (APM) is a diversified biopharmaceutical company. They develop a wide range of therapeutics, from anti-infective and anti-cancer drugs to diagnostic technologies (based on liquid biopsy). The chart shows the average index for the segment, helping investors assess how this risky portfolio approach compares to the average.
The AKIM Index for the overall market
Aptorum Group is a biopharmaceutical company developing treatments for infectious diseases, cancer, and other conditions. It is based in Hong Kong/London. This chart, showing the average (global/US) market share, serves as a benchmark. It helps assess how the company's APM and R&D history compares to overall macroeconomic trends.
